Cellular Biomedicine Group to Present at the Inaugural Meeting of Cartilage Repair and Applications Committee of the Chinese Society for Biomaterials

SHANGHAI, China and PALO ALTO, Calif., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced that management has been invited to present at the inaugural seminar of the Cartilage Repair and Applications Committee of the Chinese Society for Biomaterials.

The seminar will be held from August 7-10, 2015 at the Crowne Plaza, Yantai, China. Cheng Xiang (Chase) Dai, D.M.Sc., Senior Vice President of Clinical Development for CBMG, will present "Stem Cell Therapies for Osteoarthritis in Clinical Trials: Progress and Challenges" on Saturday, August 8, 2015 at 4:00pm. The Chinese Society for Biomaterials (CSBM) is a national, non-profit academic organization. It serves to unite and organize Chinese scientists in the biomaterials field to provide a platform of multidiscipline exchanges and communications, in order to enhance the development of biomaterials science, education, clinical applications and industry.

Cellular Biomedicine Group has been developing a world-class stem cell platform focused on providing solutions to significant unmet medical needs. The Company has had several manuscripts published in peer-reviewed journals on the subject of the treatment of osteoarthritis with mesenchymal stem cells (view Company publications here) and currently is conducting a Phase IIb clinical trial for ReJoin™ human adipose-derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The Company released positive interim results from the trial in March of this year (view press release here) and expects to complete twelve-month follow-up of all patients during the fourth quarter of 2015.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases. Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of six independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 vivian.chen@grayling.com

Source:Cellular Biomedicine Group Inc.